The coronavirus disease 2019 (COVID-19) pandemic has significantly impacted cancer care. The Dutch Oncology COVID-19 Consortium (DOCC) registry was initiated in 45 hospitals in the Netherlands to identify risk factors for a fatal outcome of COVID-19 in patients with cancer. This observational cohort study has been designed as a national quality of care registry and has been approved by the ethics committee and the Privacy Knowledge Office at Erasmus Medical Centre.
1 A questionnaire was developed to collect pseudonymized patient data ( Supplementary Appendix 1 ). The first analysis showed an increased risk of a fatal outcome for patients with cancer and COVID-19, with an overall mortality rate of 32.3%.
1 This analysis demonstrated a negative impact on COVID-19 outcome for patients with hematological malignancies or lung cancer when compared to patients with other solid tumors. However, the impact of anti-cancer therapies on the course of COVID-19, and risk factors affecting the COVID-19 outcome for patients with primary brain tumors in particular, have not yet been elucidated.
1,2 Therefore, the consequences of COVID-19 for patients with primary brain tumors, specifically those receiving oncological treatment, are unknown. Here, clinical characteristics and the outcome of COVID-19 in patients with primary brain tumors are presented.